Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

NCT01445379 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Sarcoma
Wilm's Tumor
Lymphoma
Neuroblastoma

Interventions

DRUG: Ipilimumab

Sponsor

National Cancer Institute (NCI)